abetimus

01/01/2003 - "Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo."
06/01/2009 - "In clinical trials testing new treatments for systemic lupus erythematosus (SLE), the failure of the 15-year drug development program for riquent (abetimus sodium) is the latest in a string of disappointments for a disease that has seen no new drugs approved in over 50 years."
08/01/2008 - "Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial."
02/01/2003 - "LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study."
02/01/2006 - "Abetimus sodium has been under development for the treatment of systemic lupus erythematosus since the early 1990s. "

01/01/2003 - "Previously, La Jolla Pharmaceuticals and Abbott initiated a phase II/III trial of abetimus in more than 200 patients with lupus nephritis. "
06/01/2009 - "Abetimus sodium: a medication for the prevention of lupus nephritis flares."
08/01/2008 - "To investigate whether treatment with abetimus delays renal flare in patients with lupus nephritis. "
01/01/2003 - "In September 2000, the US FDA granted orphan drug status for abetimus in the treatment of lupus nephritis. "
06/01/2009 - "Given the importance of anti-dsDNA antibodies in the pathogenesis of lupus nephritis, the Phase II and III trials were designed to evaluate whether treatment with abetimus sodium could prolong the time to renal flare in cohorts of patients at high risk of nephritic flares. "

08/01/2008 - "More patients in the abetimus group experienced > or =50% reductions in proteinuria at 1 year, compared with the placebo group (nominal P = 0.047). "

02/01/2002 - "La Jolla is developing abetimus (LJP-394), a tetrakis-oligonucleotide conjugate, for the treatment of lupus and in particular, lupus kidney disease. "

01/01/2005 - "Abetimus (LJP-394) inhibits the production of anti-dsDNA antibodies and may prevent glomerulonephritis caused by anti-DNA containing immune complexes. "